vs

Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and OLD SECOND BANCORP INC (OSBC). Click either name above to swap in a different company.

DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $93.8M, roughly 1.0× OLD SECOND BANCORP INC). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 27.3%, a 1.1% gap on every dollar of revenue. Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 15.1%).

Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

DVAX vs OSBC — Head-to-Head

Bigger by revenue
DVAX
DVAX
1.0× larger
DVAX
$94.9M
$93.8M
OSBC
Higher net margin
DVAX
DVAX
1.1% more per $
DVAX
28.4%
27.3%
OSBC
Faster 2-yr revenue CAGR
DVAX
DVAX
Annualised
DVAX
30.6%
15.1%
OSBC

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
DVAX
DVAX
OSBC
OSBC
Revenue
$94.9M
$93.8M
Net Profit
$26.9M
$25.6M
Gross Margin
Operating Margin
22.4%
Net Margin
28.4%
27.3%
Revenue YoY
17.7%
Net Profit YoY
53.0%
159.2%
EPS (diluted)
$0.21
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DVAX
DVAX
OSBC
OSBC
Q1 26
$93.8M
Q4 25
$95.2M
Q3 25
$94.9M
$95.9M
Q2 25
$95.4M
$75.1M
Q1 25
$68.2M
$73.1M
Q4 24
$72.0M
$73.2M
Q3 24
$80.6M
$71.2M
Q2 24
$73.8M
$70.8M
Net Profit
DVAX
DVAX
OSBC
OSBC
Q1 26
$25.6M
Q4 25
Q3 25
$26.9M
$9.9M
Q2 25
$18.7M
$21.8M
Q1 25
$-96.1M
$19.8M
Q4 24
$7.0M
Q3 24
$17.6M
$23.0M
Q2 24
$11.4M
$21.9M
Operating Margin
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
41.2%
Q3 25
22.4%
13.6%
Q2 25
15.1%
38.9%
Q1 25
-34.7%
35.8%
Q4 24
-2.3%
34.7%
Q3 24
12.5%
41.9%
Q2 24
7.0%
41.2%
Net Margin
DVAX
DVAX
OSBC
OSBC
Q1 26
27.3%
Q4 25
Q3 25
28.4%
10.3%
Q2 25
19.6%
29.0%
Q1 25
-141.0%
27.1%
Q4 24
9.8%
Q3 24
21.8%
32.3%
Q2 24
15.4%
30.9%
EPS (diluted)
DVAX
DVAX
OSBC
OSBC
Q1 26
$0.48
Q4 25
$0.53
Q3 25
$0.21
$0.18
Q2 25
$0.14
$0.48
Q1 25
$-0.77
$0.43
Q4 24
$0.07
$0.42
Q3 24
$0.12
$0.50
Q2 24
$0.08
$0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DVAX
DVAX
OSBC
OSBC
Cash + ST InvestmentsLiquidity on hand
$160.2M
$115.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$534.1M
$893.3M
Total Assets
$946.5M
$6.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DVAX
DVAX
OSBC
OSBC
Q1 26
$115.7M
Q4 25
$124.0M
Q3 25
$160.2M
$116.5M
Q2 25
$99.1M
$141.8M
Q1 25
$51.7M
$256.1M
Q4 24
$95.9M
$99.3M
Q3 24
$119.3M
$115.8M
Q2 24
$112.5M
$120.9M
Stockholders' Equity
DVAX
DVAX
OSBC
OSBC
Q1 26
$893.3M
Q4 25
$896.8M
Q3 25
$534.1M
$866.7M
Q2 25
$494.2M
$718.6M
Q1 25
$530.9M
$694.5M
Q4 24
$596.8M
$671.0M
Q3 24
$681.4M
$661.4M
Q2 24
$642.8M
$619.3M
Total Assets
DVAX
DVAX
OSBC
OSBC
Q1 26
$6.8B
Q4 25
$6.9B
Q3 25
$946.5M
$7.0B
Q2 25
$918.4M
$5.7B
Q1 25
$945.9M
$5.7B
Q4 24
$986.3M
$5.6B
Q3 24
$1.1B
$5.7B
Q2 24
$1.0B
$5.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DVAX
DVAX
OSBC
OSBC
Operating Cash FlowLast quarter
$33.8M
Free Cash FlowOCF − Capex
$32.6M
FCF MarginFCF / Revenue
34.4%
Capex IntensityCapex / Revenue
1.3%
Cash ConversionOCF / Net Profit
1.26×
TTM Free Cash FlowTrailing 4 quarters
$80.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
$122.3M
Q3 25
$33.8M
$35.9M
Q2 25
$23.4M
$24.2M
Q1 25
$-19.6M
$17.8M
Q4 24
$53.0M
$131.5M
Q3 24
$19.5M
$48.5M
Q2 24
$10.7M
$11.6M
Free Cash Flow
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
$117.8M
Q3 25
$32.6M
$34.7M
Q2 25
$22.0M
$23.5M
Q1 25
$-23.6M
$16.2M
Q4 24
$49.5M
$120.7M
Q3 24
$18.1M
$46.2M
Q2 24
$9.9M
$8.7M
FCF Margin
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
123.7%
Q3 25
34.4%
36.2%
Q2 25
23.0%
31.2%
Q1 25
-34.6%
22.2%
Q4 24
68.8%
165.0%
Q3 24
22.5%
64.9%
Q2 24
13.5%
12.3%
Capex Intensity
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
4.7%
Q3 25
1.3%
1.3%
Q2 25
1.5%
1.1%
Q1 25
5.8%
2.2%
Q4 24
4.8%
14.7%
Q3 24
1.7%
3.3%
Q2 24
1.1%
4.2%
Cash Conversion
DVAX
DVAX
OSBC
OSBC
Q1 26
Q4 25
Q3 25
1.26×
3.64×
Q2 25
1.25×
1.11×
Q1 25
0.90×
Q4 24
7.52×
Q3 24
1.11×
2.11×
Q2 24
0.94×
0.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DVAX
DVAX

HEPLISAVB$90.0M95%
US Department Of Defense$4.7M5%

OSBC
OSBC

Net Interest Income$81.1M87%
Noninterest Income$12.6M13%

Related Comparisons